Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder

Psychological Medicine

Volumn 38, Issue 9, 2008, Pages 1241-1249

  Ringen, P A ^a,b   Lagerberg, T V ^a   Birkenaes A B ^b   Engn, J A ^b   Faerden A ^b   Jonsdottir H ^b   Nesvag R ^c   Friis, S ^b   Opjordsmoen, S ^b   Larsen, F ^b   Melle, I ^a   Andreassen, O A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

Bipolar disorder; Schizophrenia; Substance use

Indexed keywords

CANNABIS;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG USE; FEMALE; HOSPITAL SERVICE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCHIZOPHRENIA; SEX DIFFERENCE; SUBSTANCE ABUSE;

EID: 48749090547     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S003329170700236X     Document Type: Article

References (46)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychological Association: Washington, DC.
2. Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007). Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotoxicity Research 11, 183-202.
3. Caspi A, Moffit TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a generenvironment interaction. Biological Psychiatry 57, 1117-1127.
4. Cassidy F, Ahearn EP, Carroll BJ (2001). Substance abuse in bipolar disorder. Bipolar Disorders 3, 181-188.
5. Chengappa KNR, Levine J, Gershon S, Kupfer DJ (2000). Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. Bipolar Disorder 2, 191-195.
6. Craddock N, O'Donovan MC, Owen MJ (2006). Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophrenia Bulletin 32, 9-16.
7. Crow TJ (1998). From Kraepelin to Kretschmer leavened by Schneider. The transition from categories of psychosis to dimensions of variation intrinsic to Homo sapiens. Archives of General Psychiatry 55, 502-504.
8. Daban C, Martinez-Aran A, Torrent C, Tabarés-Seisdedos R, Balanzá-Martínez V, Salazar-Fraile J, Selva-Vera G, Vieta E (2006). Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychotherapy and Psychosomatics 75, 72-84.
9. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L (2002). Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophrenia Research 56, 47-54.
10. Drake RE, Osher FC, Wallach MA (1989). Alcohol use and abuse in schizophrenia: a prospective community study. Journal of Nervous and Mental Disorder 177, 408-414.
11. D'Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T, Zimolo Z, Gueorguieva R, Krystal JH (2006). Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. Neuropsychopharmacology 31, 2767-2775.
12. Etter M, Etter J-F (2004). Alcohol consumption and the CAGE test in outpatients with schizophrenia or schizoaffective disorder and in the general population. Schizophrenia Bulletin 30, 947-956.
13. European Monitoring Centre for Drugs and Drug Addiction (2006). Annual Report 2006: The state of the drugs problem in Europe. EMCDDA: Lisbon, Portugal (http://ar2006.emcdda.europa.eu/en/home-en.html). Accessed 12 December 2006.
14. Farrell M, Howes S, Taylor C, Lewis G, Jenkins R, Bebbington P, Jarvis M, Brugha T, Gill B, Meltzer H (1998). Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Addictive Behaviors 23, 909-918.
15. Green AI, Drake RE, Brunette MF, Noordsy DL (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry 164, 402-408.
16. Green B, Young R, Kavanagh D (2005). Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry 187, 306-313.
17. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF (2005). Epidemiologic review of marijuana use and cancer risk. Alcohol 35, 265-275.
18. Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J (2006). Cannabis use and expression of mania in the general population. Journal of Affective Disorders 95, 103-110.
19. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen H-U, van Os J (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11-16.
20. Joyal CC, Hallé P, Lapierre D, Hodgins S (2003). Substance abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research 63, 297-299.
21. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D (2002). Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 62, 743-755.
22. Khantzian EJ (1985). The self medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry 142, 1259-1264.
23. Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, Conigliaro J, Haas GL (2004). Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disorders 6, 368-373.
24. Miles H, Johnson S, Amponsah-Afuwape S, Finch E, Leese M, Thornicroft G (2003). Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatric Services 54, 554-561.
25. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 28, 319-328.
26. Mueser KT, Essock SM, Drake RE, Wolfe RS, Frisman L (2001). Rural and urban differences in patients with a dual diagnosis. Schizophrenia Research 48, 93-107.
27. Mueser KT, Noordsy DL, Drake RE, Fox L (2003). Integrated Treatment for Dual Disorders: A Guide to Effective Practice. The Guilford Press: New York.
28. Mueser KT, Yarnold PR, Bellack AS (1992). Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatrica Scandinavica 85, 48-55.
29. Murray RM, Sham P, Van Os J, Zanelli J, Cannon M, McDonald C (2004). A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophrenia Research 71, 405-416.
30. Norwegian Institute for Alcohol and Drug Research (2006). Rusmidler i Norge 2006. SIRIUS: Oslo (http://www.sirus.no). Accessed 1 December 2006.
31. Office of Applied Studies, Substance Abuse and Mental Health Services Administration (2006). Drugs (heroin, PCP, LSD, cocaine, club drugs, alcohol, tobacco, marijuana, etc.) on SAMHSA's Office of Applied Studies website. US Department of Health and Mental Services: Rockville, MD (http://www.oas.samhsa.gov/drugs.cfm). Accessed 12 December 2006.
32. Picchioni MM, Murray RM (2000). Overvalued ideas about alcoholism and schizophrenia. Addiction 95, 1860-1863.
33. Potvin S, Sephery AA, Stip E (2005). A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine 36, 431-440.
34. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990). Comorbidity of mental disorders and other substance abuse. Results from the epidemiologic catchment area (ECA) study. Journal of the American Medical Association 264, 2511-2518.
35. Rehm J, Room R, van den Brink W, Kraus L (2005). Problematic drug use disorders in EU countries and Norway: an overview of the epidemiology. European Neuropsychopharmacology 15, 389-397.
36. Sherwood Brown E, Suppes T, Adinoff B, Rajan Thomas N (2001). Substance abuse and bipolar disorder: comorbidity or misdiagnosis? Journal of Affective Disorders 65, 105-115.
37. Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli R, Keck PE, Arnold LM, Amicone J (2007). Effects of co-occuring cannabis use disorders on the course of bipolar disorder after a first hospitalization of mania. Archives of General Psychiatry 64, 57-64.
38. Strakowski SM, DelBello MP, Fleck DE, Arndt S (2000). The impact of substance abuse on the course of bipolar disorder. Biological Psychiatry 48, 477-485.
39. Swartz MS, Wagner HR, Swanson JW, Scott Stroup T, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Liebermann JA (2006). Substance use in persons with schizophrenia. Baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Disorders 194, 164-172.
40. Talamo A, Centorino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ (2006). Comorbid substance abuse in schizophrenia: relation to positive and negative symptoms. Schizophrenia Research 86, 251-255.
41. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 156, 319-327.
42. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J (1998). Training and quality assurance with the Structured Clinical Interview for DSM-IV I/P (SCID). Psychiatry Research 79, 163-173.
43. Verdoux H, Mury M, Besancon G, Bourgeois M (1996). Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders. Encephale 22, 95-101.
44. Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF (2004). Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence. Journal of Affective Disorders 79, 279-283.
45. Winokur G, Turvey C, Akiskal H, Coryell W, Solomon S, Leon A, Mueller T, Endicott J, Maser J, Keller M (1998). Alcoholism and substance abuse in three groups - bipolar I, unipolars and their acquaintances. Journal of Affective Disorders 50, 81-89.
46. Ziedonis D, Williams JM, Smelson D (2003). Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. American Journal of the Medical Sciences 326, 223-230.